Literature DB >> 12297567

Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator.

Andrei V Alexandrov1, James C Grotta.   

Abstract

BACKGROUND: Arterial reocclusion has not been systematically studied despite the fact that 13% of patients in the National Institute of Neurological Diseases and Stroke rt-PA Trial deteriorated following initial improvement, suggesting that reocclusion might be responsible for poor clinical outcome in some of these patients.
METHODS: Consecutive stroke patients treated with IV tissue plasminogen activator (TPA) within 3 hours and an M1 or M2 middle cerebral artery (MCA) occlusion on pre-TPA transcranial Doppler (TCD) were monitored up to 2 hours after TPA bolus. Reocclusion was defined as the Thrombolysis in Brain Ischemia flow decrease by >/=1 grades and no hemorrhage on repeat CT. The NIH Stroke Scale (NIHSS) and modified Rankin Scores (mRS) were obtained by a neurologist independently of TCD.
RESULTS: Sixty patients with median prebolus NIHSS score of 16 (range 6 to 28, 90% with >/=10 points) had TPA bolus at 130 +/- 32 minutes (median 120 minutes, 58% within the first 2 hours). Recanalization was complete in 18 (30%), partial in 29 (48%), and none in 13 (22%) patients. Reocclusion occurred in 34% of patients with any initial recanalization (16/47): in 4 of 16 patients with complete recanalization (22%), and in 12 of 29 patients with partial recanalization (41%). Reocclusion was detected in four patients (25%) before TPA bolus, in three (19%) by 30 minutes after bolus, in three (19%) by the end of infusion, and in six (37%) by 60 to 120 minutes. Before reocclusion, those patients had earlier median timing of recanalization: 130 versus 180 minutes after stroke onset compared with those who recanalized without reocclusion (p = 0.01). Median prebolus NIHSS score in the reocclusion group was 13.5 versus 17 (rest, NS), whereas at 2 and 24 hours, their NIHSS scores were higher: 14 versus 9 and 16 versus 6 points (p </= 0.04). Deterioration followed by improvement by >/=4 NIHSS points occurred in 8 of 16 (50%) patients with reocclusion versus 10% (rest) (p < 0.05). In-hospital mortality was 25 versus 3% (p < 0.0001). At 3 months, good outcome (mRS score of 0 to 1) was achieved by 8% of patients with no recanalization, by 33% of patients with reocclusion, and by 50% of patients with stable recanalization (p </= 0.05), and mortality was 42% with no early recanalization, 33% after reocclusion, and 8% in patients with stable recanalization (p </= 0.05).
CONCLUSIONS: Early reocclusion occurs in 34% of TPA-treated patients with any initial recanalization, accounting for two-thirds of deteriorations following improvement. Reocclusion occurs more often in patients with earlier and partial recanalization, leading to neurologic deterioration and higher in-hospital mortality. However, patients with reocclusion have better long-term outcomes than patients without any early recanalization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297567     DOI: 10.1212/wnl.59.6.862

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  113 in total

1.  Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.

Authors:  Jason M Meunier; Christy K Holland; Tyrone M Porter; Christopher J Lindsell; George J Shaw
Journal:  Curr Neurovasc Res       Date:  2011-11       Impact factor: 1.990

Review 2.  Ultrasound- and microspheres-enhanced thrombolysis for stroke treatment: state of the art.

Authors:  Clotilde Balucani; Andrei V Alexandrov
Journal:  Curr Cardiol Rep       Date:  2010-01       Impact factor: 2.931

3.  Recurrent artery-to-artery embolism during intravenous t-PA therapy for acute ischemic stroke.

Authors:  Christopher D Anderson; Deborah L Bergman; Richard A Bernstein
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Paradoxically accelerated fatal brain herniation following thrombolytic therapy in acute ischemic stroke.

Authors:  Sang Won Han; Seo Hyun Kim; Ha Young Shin; Hye Yeon Choi; Chan Hee Park; Jin Kwon Kim; Ji Hoe Heo
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

Review 5.  TIMI, TIBI, TICI: I came, I saw, I got confused.

Authors:  Thomas Tomsick
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

6.  A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.

Authors:  C-C Lai; C-J Hu
Journal:  Emerg Med J       Date:  2006-02       Impact factor: 2.740

Review 7.  Endovascular therapy in hyperacute ischaemic stroke: history and current status.

Authors:  Alex M Mortimer; Marcus D Bradley; Shelley A Renowden
Journal:  Interv Neuroradiol       Date:  2013-12-18       Impact factor: 1.610

8.  Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE).

Authors:  Jean-Marc Olivot; Michael Mlynash; Vincent N Thijs; Stephanie Kemp; Maarten G Lansberg; Lawrence Wechsler; Gottfried Schlaug; Roland Bammer; Michael P Marks; Gregory W Albers
Journal:  Stroke       Date:  2008-06-19       Impact factor: 7.914

9.  A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.

Authors:  Yuko Izuhara; Nagahisa Yamaoka; Hidehiko Kodama; Takashi Dan; Shunya Takizawa; Noriaki Hirayama; Kanji Meguro; Charles van Ypersele de Strihou; Toshio Miyata
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

Review 10.  Plasminogen activators and ischemic stroke: conditions for acute delivery.

Authors:  Gregory J del Zoppo
Journal:  Semin Thromb Hemost       Date:  2013-03-28       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.